Context-dependent signaling of coincident auditory and visual events in primary visual cortex
Abstract
Detecting rapid, coincident changes across sensory modalities is essential for recognition of sudden threats or events. Using two-photon calcium imaging in identified cell types in awake, head-fixed mice, we show that, among the basic features of a sound envelope, loud sound onsets are a dominant feature coded by the auditory cortex neurons projecting to primary visual cortex (V1). In V1, a small number of layer 1 interneurons gates this cross-modal information flow in a context-dependent manner. In dark conditions, auditory cortex inputs lead to suppression of the V1 population. However, when sound input coincides with a visual stimulus, visual responses are boosted in V1, most strongly after loud sound onsets. Thus, a dynamic, asymmetric circuit connecting AC and V1 contributes to the encoding of visual events that are coincident with sounds.
Data availability
Data and software availability. The data that support the findings of this study are freely available at https://www.bathellier-lab.org/downloads or at Dryad, doi:10.5061/dryad.82r5q83. Custom analysis scripts are available as a source code file.
-
Data from: Context-dependent signaling of coincident auditory and visual events in primary visual cortexDryad Digital Repository, doi:10.5061/dryad.82r5q83.
Article and author information
Author details
Funding
Agence Nationale de la Recherche (Retour Postdoc)
- Brice Bathellier
Human Frontier Science Program (CDA)
- Evan R Harrell
- Brice Bathellier
H2020 European Research Council (ERC CoG)
- Alexandre Kempf
- Sebastian Ceballo
- Anton Filipchuk
- Brice Bathellier
Seventh Framework Programme (Marie Curie CiG)
- Brice Bathellier
Fondation pour l'Audition (Lab grant)
- Evan R Harrell
- Brice Bathellier
École Doctorale Frontières du Vivant - Programme Bettencourt (Phd fellowship)
- Alexandre Kempf
Paris-Saclay University (NeuroSaclay Brainscopes)
- Brice Bathellier
Ecole des Neurosciences de Paris (Phd fellowship)
- Sebastian Ceballo
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Karel Svoboda, Janelia Research Campus, Howard Hughes Medical Institute, United States
Ethics
Animal experimentation: All animal procedures were approved by the French Ethical Committee (authorization 00275.01).
Version history
- Received: November 29, 2018
- Accepted: May 20, 2019
- Accepted Manuscript published: May 22, 2019 (version 1)
- Accepted Manuscript updated: May 23, 2019 (version 2)
- Version of Record published: May 31, 2019 (version 3)
Copyright
© 2019, Deneux et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,907
- Page views
-
- 604
- Downloads
-
- 44
- Citations
Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Neuroscience
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.
-
- Medicine
- Neuroscience
In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.